{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:59:45Z","timestamp":1790125185984,"version":"4.0.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41571-024-00964-1","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T17:03:19Z","timestamp":1730826199000},"page":"8-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["On the cusp of targeted therapy for cancer cachexia\u00a0\u2014\u00a0what clinical benefits might we promise our patients?"],"prefix":"10.1038","volume":"22","author":[{"given":"Vickie E.","family":"Baracos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"964_CR1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/jcsm.12756","volume":"12","author":"L Martin","year":"2021","unstructured":"Martin, L. et al. Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis. J. Cachexia Sarcopenia Muscle 12, 1189\u20131202 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"964_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40024-3","volume":"14","author":"A Babic","year":"2023","unstructured":"Babic, A. et al. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Nat. Commun. 14, 4317 (2023).","journal-title":"Nat. Commun."},{"key":"964_CR3","first-page":"210","volume":"26","author":"P Klassen","year":"2023","unstructured":"Klassen, P., Schiessel, D. L. & Baracos, V. E. Adverse effects of systemic cancer therapy on skeletal muscle: myotoxicity comes out of the closet. Curr. Opin. Clin. Nutr. Metab. Care 26, 210\u2013218 (2023).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"964_CR4","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.23.01280","volume":"41","author":"EJ Roeland","year":"2023","unstructured":"Roeland, E. J., Bohlke, K., Baracos, V. E., Smith, T. J. & Loprinzi, C. L. Cancer cachexia: ASCO guideline rapid recommendation update. J. Clin. Oncol. 41, 4178\u20134179 (2023).","journal-title":"J. Clin. Oncol."},{"key":"964_CR5","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.22.01997","volume":"41","author":"L Sandhya","year":"2023","unstructured":"Sandhya, L. et al. Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J. Clin. Oncol 41, 2617\u20132627 (2023).","journal-title":"J. Clin. Oncol"},{"key":"964_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409515","author":"JD Groarke","year":"2024","unstructured":"Groarke, J. D. et al. Ponsegromab for the treatment of cancer cachexia. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2409515 (2024).","journal-title":"N. Engl. J. Med."},{"key":"964_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389942","volume":"43","author":"KC Kadakia","year":"2023","unstructured":"Kadakia, K. C., Hamilton-Reeves, J. M. & Baracos, V. E. Current therapeutic targets in cancer cachexia: a pathophysiologic approach. Am. Soc. Clin. Oncol. Educ. Book 43, e389942 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"964_CR8","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland, E. J. et al. Management of cancer cachexia: ASCO guideline. J. Clin. Oncol. 38, 2438\u20132453 (2020).","journal-title":"J. Clin. Oncol."},{"key":"964_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel, J. S. et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17, 519\u2013531 (2016).","journal-title":"Lancet Oncol"},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/jcsm.13133","volume":"14","author":"K Amano","year":"2023","unstructured":"Amano, K. et al. Development and validation of questionnaires for eating-related distress among advanced cancer patients and families. J. Cachexia Sarcopenia Muscle 14, 310\u2013325 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00964-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00964-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00964-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:02:49Z","timestamp":1734530569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00964-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00964-1","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"5 November 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.E.B declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}